BNIP3 as a potential biomarker for the identification of prognosis and diagnosis in solid tumours

Background Traditional radiotherapy and chemotherapy have been intensively studied for their role in the treatment of tumours. However, these therapies often cause side effects for patients, which calls for the development of novel treatment options for tumours. B-cell lymphoma-2 (Bcl-2)/adenovirus...

Full description

Saved in:
Bibliographic Details
Published in:Molecular cancer 2023-08, Vol.22 (1), p.1-143, Article 143
Main Authors: Yu, Qin, Fu, Wenhao, Fu, Yutang, Ye, Wenjing, Yan, Huiqiong, Yu, Zecheng, Li, Ruirui, Cai, Yili, Chen, Yuxin, Wang, Lingyun, Wei, Xianqiao, Chen, Yangkun, Zhang, Yuheng, Ying, Huazhong, Tang, Furong, Dai, Fangwei, Han, Wei
Format: Article
Language:English
Subjects:
Apoptosis
Autophagy
Bcl-2 protein
Biomarkers
BNIP3
BNIP3 protein
Brain tumors
Breast cancer
Cancer
Cancer therapies
Cell growth
Chemotherapy
Correlation analysis
Correspondence
Development and progression
Diagnosis
DNA damage
Gene silencing
Genetic engineering
Gliomas
Homeostasis
Immune infiltration
Ligands
Lymphocytes B
Lymphomas
Medical prognosis
Metastasis
Olfaction
Pan-cancer analysis
Prognostic biomarker
Proteins
Radiation therapy
Radiotherapy
Renal cell carcinoma
Sarcoma
Signal transduction
Solid tumors
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Traditional radiotherapy and chemotherapy have been intensively studied for their role in the treatment of tumours. However, these therapies often cause side effects for patients, which calls for the development of novel treatment options for tumours. B-cell lymphoma-2 (Bcl-2)/adenovirus E1B 19 kDa-interacting protein 3 (BNIP3) reportedly apoptosis-inducing effects in tumour cells and is associated with the progression and treatment of multiple tumours. Nevertheless, little is known about its potential role in tumour diagnosis and targeted therapy. Findings The results of the study demonstrated that the interaction of BNIP3 with HDAC1 may affect the progression of breast invasive cancer (BRCA), sarcoma (SARC), kidney renal clear cell carcinoma (KIRC), and low-grade glioma (LGG). BNIP3 seemed to exert its effects in BRCA and SARC primarily through gene silencing and integrator complex, and in KIRC and LGG, mainly by affecting olfactory function, suggesting that targeted therapy can be developed based on the above signalling pathway and downstream molecules. Interpretation BNIP3 has emerged as a promising therapeutic and diagnostic target for BRCA, SARC, KIRC, and LGG, providing new insights into tumour molecular therapies in the clinic. Keywords: BNIP3, Immune infiltration, Pan-cancer analysis, Prognostic biomarker, Diagnosis
ISSN:1476-4598
1476-4598
DOI:10.1186/s12943-023-01808-9